Atorlip 5 is a prescription medication containing atorvastatin calcium, specifically formulated to address elevated cholesterol levels and support cardiovascular health. As a member of the statin class, it works by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis in the liver. This medication is indicated for patients with hyperlipidemia, helping to reduce low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B, while increasing high-density lipoprotein (HDL) cholesterol. Clinical evidence supports its role in reducing the risk of myocardial infarction, stroke, and revascularization procedures in adult patients with multiple risk factors for heart disease. Proper use under medical supervision can contribute significantly to long-term lipid management and atherosclerosis prevention.

Features

• Active ingredient: Atorvastatin calcium 5 mg per tablet
• Pharmaceutical form: Film-coated tablets
• Mechanism: Selective, competitive inhibitor of HMG-CoA reductase
• Bioavailability: Approximately 14%
• Half-life: 14 hours; active metabolites have half-lives of 20–30 hours
• Excretion: Primarily via hepatic metabolism and biliary elimination
• Packaging: Blister packs of 10, 30, or 90 tablets

Benefits

• Significantly reduces LDL cholesterol levels by 30–50% at standard doses
• Lowers triglyceride levels and modestly increases HDL cholesterol
• Reduces the risk of cardiovascular events, including heart attack and stroke
• Slows the progression of atherosclerosis and coronary artery disease
• Provides 24-hour lipid-lowering effect with once-daily dosing
• Supported by extensive clinical trial data demonstrating efficacy and safety

Common use

Atorlip 5 is primarily prescribed for the treatment of dyslipidemias, including primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. It is indicated as an adjunct to diet when diet and other nonpharmacological measures have proven inadequate. Additionally, it is used to reduce the risk of myocardial infarction, stroke, unstable angina, and revascularization procedures in adults with multiple risk factors but without established coronary heart disease. The medication may also be prescribed for homozygous familial hypercholesterolemia as part of a comprehensive lipid-lowering regimen.

Dosage and direction

The recommended starting dose is Atorlip 5 (5 mg) once daily, which may be adjusted based on lipid response and tolerability. Doses can be titrated up to a maximum of 80 mg daily, though most patients achieve desired lipid levels with 10–20 mg daily. Administration can occur with or without food, preferably at the same time each day. Tablets should be swallowed whole with water and not crushed or chewed. Dose adjustments are necessary in patients taking certain concomitant medications or with hepatic impairment. Regular lipid profiles should be monitored at 4-week intervals after initiation or dose adjustment.

Precautions

Liver function tests should be performed before initiating therapy and periodically thereafter. Patients should report any unexplained muscle pain, tenderness, or weakness immediately, as these may signal myopathy or rhabdomyolysis. Use with caution in patients consuming substantial quantities of alcohol or with a history of liver disease. Blood glucose levels should be monitored, as statins may increase HbA1c and fasting serum glucose levels. Not recommended during pregnancy or in women planning pregnancy due to potential fetal harm. Patients should be advised about the rare risk of hemorrhagic stroke.

Contraindications

Active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. Hypersensitivity to atorvastatin or any component of the formulation. Pregnancy, lactation, and women of childbearing potential not using adequate contraception. Concomitant use with strong CYP3A4 inhibitors such as itraconazole, clarithromycin, or HIV protease inhibitors. Severe renal impairment (CrCl <30 mL/min) requires careful consideration and possibly alternative therapy.

Possible side effect

Common adverse reactions (≥2%) include headache, myalgia, arthralgia, nausea, diarrhea, dyspepsia, and elevated liver enzymes. Less frequently reported effects include rash, insomnia, and nasopharyngitis. Serious but rare side effects include rhabdomyolysis with renal dysfunction, hepatotoxicity, immune-mediated necrotizing myopathy, and cognitive impairment. Some patients may experience increased blood glucose levels and development of type 2 diabetes. Allergic reactions, including angioedema and anaphylaxis, have been reported in post-marketing experience.

Drug interaction

Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) significantly increase atorvastatin exposure and risk of myopathy. Concurrent use with gemfibrozil or other fibrates increases myopathy risk. Cyclosporine, niacin, and colchicine may also elevate myopathy risk. Oral contraceptives containing ethinyl estradiol and norgestrel show increased AUC values when co-administered. Digoxin levels may increase slightly with concomitant use. Antacids containing magnesium and aluminum hydroxide decrease atorvastatin plasma concentrations slightly when administered simultaneously.

Missed dose

If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. Consistency in daily administration is important for maintaining stable lipid-lowering effects.

Overdose

There is no specific antidote for atorvastatin overdose. Supportive measures should be instituted, and liver function and CK levels monitored. Symptoms may include gastrointestinal disturbances and elevated transaminase levels. In cases of significant overdose, consider activated charcoal administration if presented soon after ingestion. Hemodialysis is unlikely to be effective due to high protein binding. Medical attention should be sought immediately in suspected overdose situations.

Storage

Store at room temperature (15–30°C) in the original container, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Tablets should not be removed from blister packs until immediately before administration. Avoid storage in bathrooms or other areas with high humidity.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Atorlip 5 is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and patients should follow their physician’s instructions regarding dosage, monitoring, and duration of treatment. The full prescribing information should be consulted before initiating therapy.

Reviews

Clinical studies demonstrate that atorvastatin 5 mg provides effective LDL-C reduction with a favorable safety profile. In the ASCOT-LLA trial, atorvastatin 10 mg reduced coronary events by 36% in hypertensive patients with normal cholesterol levels. Real-world evidence supports its efficacy in diverse patient populations, though individual responses vary based on genetic factors, adherence, and concomitant risk factors. Patient satisfaction surveys indicate good tolerability, with most users reporting minimal side effects when properly dosed and monitored.